We Offer Worldwide Shipping
Login Wishlist

Isofraxidin 7-O-β-D-glucoside

$672

  • Brand : BIOFRON

  • Catalogue Number : BD-P0889

  • Specification : 98.0%(HPLC&TLC)

  • CAS number : 483-91-0

  • Formula : C17H20O10

  • Molecular Weight : 384.33

  • PUBCHEM ID : 5318566

  • Volume : 25mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0889

Analysis Method

HPLC,NMR,MS

Specification

98.0%(HPLC&TLC)

Storage

2-8°C

Molecular Weight

384.33

Appearance

Powder

Botanical Source

Structure Type

Coumarins

Category

Standards;Natural Pytochemical;API

SMILES

COC1=C(C(=C2C(=C1)C=CC(=O)O2)OC)OC3C(C(C(C(O3)CO)O)O)O

Synonyms

6,8-Dimethoxy-2-oxo-2H-chromen-7-yl Beta-D-glucopyranoside/6,8-Dimethoxy-2-oxo-2H-chromen-7-yl β-D-glucopyranoside/2H-1-Benzopyran-2-one, 7-(β-D-glucopyranosyloxy)-6,8-dimethoxy-

IUPAC Name

6,8-dimethoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one

Applications

Calycanthoside is a natural compound isolated from Angelica tenuissima[1].

Density

1.5±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

246.2±25.0 °C

Boiling Point

675.0±55.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C17H20O10/c1-23-8-5-7-3-4-10(19)26-14(7)16(24-2)15(8)27-17-13(22)12(21)11(20)9(6-18)25-17/h3-5,9,11-13,17-18,20-22H,6H2,1-2H3/t9-,11-,12+,13-,17+/m1/s1

InChl Key

IKUQEFGEUOOPGY-QSDFBURQSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:483-91-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29707155

Abstract

The choice of surgical treatment for hepatocellular carcinoma (HCC) depends on several prognostic variables, among which histological features, like microvascular invasion and tumor grade, are well established. This study aims to identify the tissue miRNAs predictive of recurrence after liver resection in “histologically advanced” HCC. We selected 54 patients: 15 retrospective resected patients without recurrence (group A), 19 retrospective resected patients with HCC recurrence (group B), and 20 prospective patients (group C), with 4 recurrence cases. All selected HCC were “histologically advanced” (high Edmondson grade and/or presence of microvascular invasion). A wide spectrum of miRNAs was studied with TaqMan Human microRNA Arrays; qRT-PCR assays were used to validate results on selected miRNAs; immunohistochemistry for IGF2 was applied to study the mechanism of miR-483-3p. As a result, a significant differential expression between group A and B was found for 255 miRNAs. Among them we selected miR-483-3p and miR-548e (P<0.001). As a single variable (group C), HCC with miR-483-3p downregulation (mean fold increase 0.21) had 44.4% of recurrence cases; HCC with miR-483-3p upregulation (mean fold increase 5.94) showed no recurrence cases (P=0.011). At immunohistochemistry (group C), the HCC with loss of cytoplasmic IGF2 expression showed a down-regulation of miR-483-3p (fold increase 0.57). In conclusion, in patients with “histologically advanced” HCC, the analysis of specific tissue miRNAs (particularly miR-483-3p) could help identify the recurrence risk and choose which treatment algorithm to implement (follow-up, resection or transplantation). This could have an important impact on patient survival and transplantation outcome, improving organ allocation.

KEYWORDS

hepatocellular carcinoma, IGF2, liver resection, miRNA, tumor recurrence

Title

Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas

Author

Francesco Vasuri,1 Silvia Fittipaldi,1 Vanessa De Pace,2 Laura Gramantieri,3 Valentina Bertuzzo,2 Matteo Cescon,2 Antonio D. Pinna,2 Michelangelo Fiorentino,1 Antonia D’Errico,1 and Matteo Ravaioli2

Publish date

2018 Apr 3;

Title

ESICM LIVES 2016: part three Milan, Italy. 1-5 October 2016

Publish date

2016 Sep 29

Title

ESICM LIVES 2016: part two Milan, Italy. 1-5 October 2016

Publish date

2016 Sep 29